GTXI: Summary for GTx, Inc. - Yahoo! Canada Finance - Share Prices, Charts, News and more

MORE ON GTXI

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

GTx, Inc. (NGM:GTXI) Delayed quote data

Last Trade:	4.16 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	4.16
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	4.00

Day's Range:	N/A - N/A
52wk Range:	3.22 - 13.59
Volume:	0
Avg Vol (3m):	379,086
Market Cap:	151.51M
P/E (ttm):	N/A
EPS (ttm):	-1.35
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add GTXI to Portfolio

Download Data

HEADLINES

•	This Week's Failed Trials, Missed Targets in Biotech
	at Seeking Alpha (Sun, Dec 20)

•	Movers roundup: Waste Services, GTx
	AP (Mon, Dec 14)

•	GTx shares fall after delay leads to job cuts
	AP (Mon, Dec 14)

•	GTx Announces Reduction in Force
	Business Wire (Fri, Dec 11)

•	GTX INC /DE/ Financials
	EDGAR Online Financials (Fri, Nov 13)

•	GTx, Inc. Earnings Call scheduled for 9:00 am ET today
	CCBN (Mon, Nov 9)

•	GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition
	EDGAR Online (Mon, Nov 9)

•	3 Stocks Attracting Top Investors
	at Motley Fool (Wed, Nov 4)

•	Hemispherx Cops to Ampligen FDA Delay
	at TheStreet.com (Tue, Nov 3)

•	GTx shares crater on FDA rejection
	at MarketWatch (Mon, Nov 2)

•	YRC Worldwide, LDK Solar: Midday Volume Plays
	at TheStreet.com (Mon, Nov 2)

More Headlines for GTXI...

ANALYST

EPS Est (next year) (Dec-09) :	-1.33
EPS Est (in 2 years) (Dec-10) :	-0.88
Avg Rec (current)*:	3.3
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle loss, and other serious medical conditions in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•

	Sign In [New User? Sign Up]	Finance Home \|Help

GTX Inc. (GTXI)